Zeta DOG-1 Antibody. Zeta’s mouse monoclonal antibody recognizes DOG-1 (Discovered On GIST 1), a protein that is elevated in the gastrointestinal stromal tumors (GIST’s), c-kit signaling-driven mesenchymal tumors of the GI tract. DOG-1 is rarely expressed in other soft tissue tumors, which due to appearance, may be difficult to diagnose. The DOG-1 antibody immunoreactivity has been reported in 97.8 percent of scorable GIST’s, including all c-kit negative GIST’s. Overexpression of DOG-1 has been suggested to aid in the identification of GISTs, including Platelet-Derived Growth Factor Receptor Alpha mutants that fail to express c-kit antigen. The overall sensitivity of DOG1 and c-kit in GIST’s is nearly identical: 94.4% vs. 94.7%.
DOG-1 is primarily used in the diagnosis of gastrointestinal stromal tumor (GIST), although its biological role is not fully understood. The DOG-1 codes for three known splice variants, one of which is a transmembrane protein that encodes the chloride channel protein anoctamn 1. DOG-1 is expressed in the luminal surface of the gastric body and antral mucosa, salivary glands, pancreatic acini, intrahepatic bile ducts, gallbladder glandular elements, as well as breast and prostatic myoepithelial and basal cells. In the interstitial cell of Cajal, DOG-1 is found to contribute to the generation of pacemaker electrical activity that is important for the physiologic motility of the gastrointestinal tract.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.